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Introduction
The term incidentaloma is derived from “incidental tumor,” describ-
ing a mass discovered on imaging by pure chance1. When discussing 
adrenal incidentalomas (AIs), this refers to a finding of a visible 
adrenal mass greater than 1cm in diameter found on imaging per-
formed for other medical causes2. In general, adrenal tumors are 
detected in 0.4% of abdominal ultrasounds and occur with ten times 
greater frequency in those with a positive cancer history3. Exclusion 
criteria for AIs include patients who present with manifestations 
of adrenal dysfunction2 and those with extra-adrenal cancers in the 
process of stratification4.
Advances in modern diagnostic methods have produced a greater 
prevalence of AIs, especially due to advances in CT and MRI 
technology3. Incidental adrenal masses are found in 2–4% of 
abdominal CT scans and the frequency increases in correlation 
with the patient’s age - adding 0.2% in the third decade of life, 
up to 7% in those greater than 70 years old4. Among these, non-
functional adenoma remains the most frequent (60–85%), while a 
minority present as functional adenomas (5–16%)5. Of functional 
masses, 6% consist of pheochromocytomas, 5% are subclini-
cal Cushing Syndrome, 5% are adrenal carcinoma, 2% prove to 
be a metastasis, and the rest belong to other etiologies, such as 
myelolipomas, hematomas, cysts, or lymphomas6,7.
Nevertheless, the retroperitoneal location increases the difficulty 
of detection during a standard physical exam. This often leads 
to the late diagnosis of such tumors only when clinical systemic 
manifestation is present - in the case of functional incidentalomas - 
or the compromise of the adjacent tissues secondary to abnormal 
gland growth8. According to endocrinology guidelines, both hor-
monal and radiographic evaluation must be performed in order to 
rule out subclinical states9,10. In general, masses ≥4cm are removed 
surgically, independent of functionality. Furthermore, all functional 
tumors and those with malignant characteristics undergo an adrena-
lectomy under endocrinologic supervision. Non-functional adeno-
mas, small myelolipomas, and benign asymptomatic cysts do not 
require surgical intervention10.
With this in mind, providers must remember two primary questions, 
first asking “Is the mass hormonally active?” as this differentiates 
between functional and nonfunctional masses5,6. Additionally, 
asking “Are there malignant characteristics?” proves equally 
important. This is determined by the radiologic imaging that 
look for heterogeneity, poorly delimited borders, the presence of 
necrosis, hemorrhage, calcification, or an attenuation coefficient 
greater than 20 Hounsfield Units7.
This case report describes a giant right upper quadrant incidenta-
loma in an asymptomatic patient that was initially thought to be a 
hepatic hemangioma, due to its size and location, which was later 
confirmed to be an adrenal tumor.
Case Report
A 54 year old asymptomatic female patient was seen by her family 
physician in Marcaibo, Venezuela, for her annual health exam in 
January 2014 in a primary care center. She had no complaints, 
except for recent unintended weight gain. Her past medical and 
surgical history are notable for a left breast lumpectomy (1973), 
a salpingectomy (1994), a hysterectomy without oophorectomy 
for NIC III (2005), and a left unilateral oophorectomy for ovarian 
torsion (2007). The patient used no medications and has no known 
allergies, and denied tobacco, alcohol, or drug use. The patient is 
monogamous and happily married. Her family history is notable for 
a sister who died of Hodgkin Lymphoma.
On physical exam, the patient was afebrile with normal vital signs. 
Her weight was 92.5 kg, 1.74 meters tall, with a BMI of 30.6. She 
appeared well hydrated with moist mucous membranes. She had an 
unremarkable exam - no findings of violaceous striae, acanthosis, 
acrochordons, or signs of virilization.
Laboratory results showed a normal complete blood count, mixed 
dyslipidemia, fasting blood glucose levels >125 mg/dl (normal 
range, 70–100 mg/dl) on more than two occasions, and HOMA1-
IR index >2.5 (normal index, ≤ 2.5) (Table 1); meeting the diag-
nostic criteria for type 2 diabetes mellitus (DM2) and metabolic 
Table 1. Results of laboratory exams.
Laboratory October 2013
November 2013 - January 
2014 (initial treatment)
April 2014 (treatment 
control - pre-operative)
Cholesterol - Total 264,30 mg/dl 247 mg/dl 121.30 mg/dl
HDL - C 53 mg/dl 41 mg/dl 36 mg/dl
LDL - C 164,64 mg/dl 165 mg/dl 67.64 mg/dl
Triglycerides 236 mg/dl 204 mg/dl 86 mg/dl
Creatinine 0.6 mg/dl 0.7 mg/dl 0.8 mg/dl
Uric Acid 6.9 mg/dl 5.0 mg/dl 4.2 mg/dl
Urea 23 mg/dl 21 mg/dl 29 mg/dl
AST 19.28 UI/L 9 UI/L 21.92 UI/L
ALT 17.00 UI/L 10 UI/L 21.11 UI/L
Blood Glucose 148,80 mg/dl 129 mg/dl 94.35 mg/dl
Fasting Insulin 11.50 uIU/ml
Postprandial Insulin 103.30 uIU/ml
*HOMA 3,5
*HOMA-IR = [Basal Insulin (IU/ml) × GA (mg/dL)/405]
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Table 2. Specific cortical and medullary adrenal hormones (February 2014).
Adrenal cortex
Zona reticularis Zona fasciculata
Hormone Result Hormone Result
Testosterone - Total 0.09 ng/ml (VN: 0,06-0,82) Urine cortisol occasional 12.30 ug/dl (VN: 0,20-50,00)
Free Testosterone 0.79 pg/ml (VN: 1,20-6,60) Cortisol (am) 5.50 ug/dl (VN:5-25)
DHEA-S 76.60 ug/dl (VN: 35,40-256,30) Cortisol (pm) 4.21 ug/dl
Androstenedione 1,10 ng/nl (VN: 0,85-10,00)
Adrenal medulla (in urine)
Catecholamines* Metanephrines**
Adrenaline 13 mcg/24 hrs (VN: < 20) Metanephrine/Urine 43.0 mcg/L
Dopamine 706 mcg/24 hrs (VN:<600) Metanephrine/24 hrs 166.0 mcg/24 hrs (25,0-312,o)
Noradrenaline 10 mcg/24 hrs (VN: < 90)
24 hr urine collection: *3.377 ml/24 hrs and **3.860.0 ml/24 hrs
Figure 1. Abdominal ultrasound of the patient. A hyperechogenic 
5.6 × 7.3 cm image is observed in segment V of the right hepatic 
lobe suggestive of an incidental hemangioma.
Figure 2. Triphasic abdominal MRI showing a right 7.0 x 6.0 cm 
adrenal incidentaloma. Left panel, longitudinal cut; right panel, 
transverse cut. Performed using SIEMENS Magneton Essenza 
1.5 TESLA.
syndrome. Initial recommendations were lifestyle changes, includ-
ing 30 minutes walks five days a week, and a nutritionist consult. 
Additionally, pharmacotherapy, sitagliptin/metformin (Janumet®, 
50/1000mg) 1 tab daily, ezetimibe/simvastatin (Vytorin®, 10/40 mg) 
1 tab daily, gemfibrozil (Lipontal®, 900 mg) 1 tab daily, and orlistat 
(Xerogras®, 120 mg) 1 cap daily, was initiated.
Simultaneously, a right upper quadrant ultrasound was ordered 
showing slight hepatic steatosis, as well as a round space occu-
pying lesion with well-defined hyperechoic borders measuring 
5.6×7.3cm in segment V of the right lobe suggestive of a heman-
gioma. Of note, a bilateral non-obstructive nephrolithiasis was 
observed (Figure 1). Due to these findings, the patient was referred 
to a local hospital diagnostic center for imaging studies, a triphasic 
hepatic MRI was performed as part of an additional workup. This 
identified a 7.0×6.0cm right adrenal space occupying lesion sug-
gestive of a large adrenal adenoma (Figure 2). A hormone profile 
was performed with normal results - classifying this mass as a 
non-functional adenoma. Lack of reagents in local laboratories 
caused that the patients moved to Avila Clinic in Caracas 
(Capital of Venezuela) (Table 2). The work up was completed with a 
serologic evaluation to rule out fungal infection with negative 
results for mycoplasma IgM (0.15; normal range: 0.00 – 0.90).
In April 2014, a right subcostal adrenalectomy was performed in 
at a level three hospital so as to ensure the presence of an inten-
sive care unit due to the potential bleeding risk. The pathology 
report described a 4×7×6cm adrenal mass with a grey-yellow 
surface covered partially with a thick grey capsule with brown 
areas with a hemorrhagic and yellow adipose center. The micro-
scopic evaluation showed an external layer of clear cortical cells 
of the adrenal granulosa; a center made of mature adipocytes and 
all three hematopoietic cell lines without calcifications or fibrosis. 
The final diagnosis was determined to be an adrenal myelolipoma 
(Figure 3).
The patient experienced no post-surgical complications. She has 
subsequently completed regular physical activity and continues with 
Page 4 of 10
F1000Research 2017, 6:1140 Last updated: 31 JUL 2017
Figure 3. Myelolipoma evaluation. Surgical specimen, macroscopic. 
Amado Polyclinic, Maracaibo- Edo Zulia (10/04/2013).
the same treatment at the same dosage. Standard laboratory checks 
at three months showed notable improvement in all parameters.
Discussion
Adrenal myelolipoma is a rare encapsulated benign tumor described 
first in 1905 by Gierke11 and later named by the French pathologist 
Charles Oberling in 192912,13. These tumors are metabolically inac-
tive - or nonfunctional - and composed of adipose and hematopoietic 
cells originating from the adrenal stroma. They are predominantly 
asymptomatic and tend to be discovered incidentally13–15.
The incidence of these tumors is between 0.08–0.4%12, although 
they comprise 15% of the AIs discovered due to advances in 
radiographic imagery13. They frequently present between the fifth 
and seventh decades of life without a predominance in either sex 
- though there is a greater incidence in the right adrenal gland15. 
Though the adrenal location predominates, there have been 
discoveries in other locations with a preference for the presacral 
region, and less frequently in gastric, hepatic, ganglionic lym-
phatics, cranium, and spleen locations16. These statistics are in 
accordance with this case report.
The etiology for adrenal myelolipoma is not clear with numerous 
theories being proposed. Some suggest a metaplasia of the adrenal 
and myeloid cells that migrated during embryogenesis, extramed-
ullary hematopoiesis, and embolization of osseous medulla 
elements17. This metaplasia may occur as a response to necro-
sis, stress, infections, or prolonged adrenocorticotropic hormone 
(ACTH) stimulation11,18. For example, Al-Bahri et al.19 reported a 
case of a large bilateral myelolipoma in a 39 year old male with 
a history of congenital adrenal hyperplasia secondary to a 21-α 
hydroxylase deficiency treated with steroids starting in child-
hood. This was later stopped during adolescence with a subsequent 
myelolipoma development - supporting the theory that ACTH 
stimulation causes adrenocortical metaplasia. Finally, giant 
myelolipomas usually are associated with hematologic disorders, 
like hereditary spherocytosis, thalassemia, and falciform anemia, as 
a response to adrenal stimulation from erythropoietin20.
Recent cytogenetic analyses propose that myelolipomas are out-of-
place masses of myeloid cells. Mitsui et al. described an extremely 
rare case with the presence of osseous tissue with cells similar to 
osteoblasts21. Upon immunohistochemical analysis, there were 
positive results for bone morphogenetic protein 2 (BMP2), which 
acts as an inductor for osseous formation and the β-catenin that 
intervenes in the signal pathway. This finding can help give insight 
into myelolipoma tumorigenesis.
Researchers have also identified (3,21)(q25;p11) chromosomal 
translocations in patients with myelolipomas and hematological 
neoplasias18. Because of this, some consider myelolipomas as vari-
ants of multiple endocrine neoplasias22, while others recommend 
that they be grouped with other tumors, such as lipomas, terato-
mas, liposarcomas, or angiomyolipomas23,24. Despite its benign 
characteristics, the pathological studies and immunohistochemical 
evaluation (not performed due to lack of reagents) was recom-
mended, because of the patient’s personal and family history that 
increased risk for malignant results.
Though these tumors are nonfunctional13–15,25, there may be the 
coexistence of myelolipoma with hyperplasia in any of the three 
adrenal cortical zones26,27. For these cases, treatment is adrenalec-
tomy (just as in any case of myelolipomas >6cm) independent of its 
functionality, due to the risk of intratumoral necrosis, hemorrhage 
from rupture or compression of adjacent structures due to mass 
effect28. Alternatively, nonfunctional tumors ≤4cm with benign 
characteristics are recommended to be periodically monitored with 
radiological and biochemical evaluations. For masses between 4 
and 6cm, the surgical intervention should be based on presenting 
characteristics, growth rate, and the patient’s preference7,29.
It is estimated that 20% of AIs will have subclinical hormone pro-
duction and these patients represent an at-risk population with 
greater risk of metabolic disorders and cardiovascular disease7,19. 
In the present case, the patient’s hormone values were within 
normal parameters - ruling out subclinical states, including Conn’s 
Syndrome (hyperaldosteronism), Cushing Syndrome or pheochro-
mocytoma. Nevertheless, the presence of myelolipoma is associated 
with obesity, DM2 and dyslipidemia warranting pharmacological 
intervention30. This was further emphasized through a retrospective 
review of 34 AIs in patients of both sexes over the age of 50, where 
over half suffered from hypertension, 20.6% had DM2, and 37% 
had obesity. Of these, 80% were histopathologically confirmed to 
be adenomas with one being a myelolipoma25,30.
As strengths, we can point out the collaboration between differ-
ent levels of medical attention and the shared effort of the family 
and the patient to travel to another state to complete this medical 
Care. Despite the Venezuelan medical assistance crisis, a relatively 
quick resolution of the case was achieved. Lastly, we emphasize the 
compliance with the protocol for proper management of adrenal 
tumors.
The limitations include the inability to perform the hormonal 
profile and determine whether the tumor was functional or not. 
Additionally, the choice of imaging could have been better. 
Page 5 of 10
F1000Research 2017, 6:1140 Last updated: 31 JUL 2017
Specifically, the use of MRI instead of CT is not the first choice for 
the diagnosis of the myelolipoma; however, this occurred because 
the initial diagnosis was directed towards a hepatic hemangioma.
Conclusions
Adrenal myelolipomas are rare benign tumors that are generally 
asymptomatic, whose size ranges from a few millimeters to over a 
dozen centimetres. Much uncertainty exists surrounding the etiol-
ogy of these masses with continued debate in the current litera-
ture on whether or not they are true neoplasms or manifestations 
secondary to a reactive process26. In general, surgical management 
depends on hormone production, tumor size, high risk features on 
imaging and patient consent. Yet additional studies and information 
are needed to better understand myelolipomas, their etiology, and 
clinical management.
Lastly, this case demonstrates how family physicians can manage 
various aspects of patient care through the facilitation of medical 
treatments, surgical interventions, and ensuring a proper multidisci-
plinary approach based on the endocrinology clinical guidelines.
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